复星医药(600196)
 
 
  日线
顶尖财经网欢迎您！
  K线
 
 最新动态
  投资评级

研究机构 评级日期 最新评级 上次评级
中国银河 2025-10-28 买入 买入
天风证券 2025-09-14 买入
中信证券 2025-09-01 买入
  盈利预测
据复星医药二季报分析：

  盈利能力维持稳定，主营获利能力保持稳定

  成长能力明显改善，营利增速步入上升通道

  偿债能力维持稳定，短期债务风险存在但可以控制

  运营能力维持稳定，应收账款周转速度需加快

  现金流能力有所加强，公司现金回收质量略差

  财务数据
2025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-312023-12-31
每股收益(元)0.950.640.291.040.750.460.230.89
每股净资产(元)17.9917.7517.9417.6917.7117.5717.3417.10
每股资本公积金(元)6.126.106.246.216.566.576.306.31
每股未分配利润(元)10.5710.2710.239.949.679.379.419.18
每股经营性现金流(元)1.270.800.401.681.120.710.341.28
净资产收益率(%)5.303.581.615.904.322.661.335.29
营业总收入(元)293.93亿195.14亿94.20亿410.67亿309.12亿204.63亿101.57亿414.00亿
营业总收入同比增长(%)-4.91-4.63-7.26-0.800.69-4.36-6.56-5.81
归属净利润(元)25.23亿17.02亿7.65亿27.70亿20.11亿12.25亿6.10亿23.86亿
归属净利润同比增长(%)25.5038.9625.4216.08-11.93-31.09-38.22-36.04
扣非净利润(元)15.73亿9.61亿4.10亿23.14亿18.36亿12.54亿6.09亿20.11亿
扣非净利润同比增长(%)-14.32-23.39-32.5615.1024.58-8.64-33.81-48.08
毛利率(%)48.2048.1247.7747.9748.6048.8750.0147.84
净利率(%)10.4010.7610.008.558.157.577.746.99
资产负债率(%)48.5249.2448.4348.9848.6449.0549.4250.10
存货周转率(次)2.131.420.692.842.091.370.672.97
  主营收入+营业利润
 
  净利润+每股收益
  股东权益+未分配利润
  
  总资产+负债
  投资要点
  • 总资产(亿元)
  • 负债(亿元)
    截至第三季度最新总资产11812073.85万元，负债5730913.86万元。

利润表
报告期2025-09-302025-06-302025-03-312024-12-31
营业总收入29,393,385,360.9119,514,431,849.599,420,322,797.3441,067,195,862.59
营业总成本28,415,595,587.618,904,362,502.049,130,342,151.6839,397,511,520.64
其他经营收益
营业利润3,906,765,379.572,761,208,390.861,358,771,228.344,245,103,909.31
利润总额3,837,343,481.792,718,481,583.081,347,541,972.014,169,281,679.72
净利润3,056,091,951.682,100,210,564.8941,566,276.853,512,440,385
每股收益
其他综合收益-385,229,723.22-32,659,264.99-110,471,546.9543,142,250.33
综合收益总额2,670,862,228.462,067,551,299.81831,094,729.93,555,582,635.33
资产负债表
报告期2025-09-302025-06-302025-03-312024-12-31
流动资产:
流动资产合计32,145,481,005.8834,342,267,603.1934,438,609,708.9334,491,060,582.73
非流动资产:
非流动资产合计85,975,257,507.1384,485,669,451.9183,551,879,181.1682,969,506,766.54
资产总计118,120,738,513.01118,827,937,055.1117,990,488,890.09117,460,567,349.27
流动负债:
流动负债合计35,086,945,012.2236,023,336,557.9735,500,536,915.2537,452,669,252.79
非流动负债:
非流动负债合计22,222,193,608.3222,489,492,119.0321,640,050,046.7620,074,169,184.16
负债合计57,309,138,620.5458,512,828,67757,140,586,962.0157,526,838,436.95
所有者权益(或股东权益):
归属于母公司股东权益合计48,028,502,901.0547,397,623,662.6747,923,631,569.9547,261,106,860.73
股东权益合计60,811,599,892.4760,315,108,378.160,849,901,928.0859,933,728,912.32
负债和股东权益合计118,120,738,513.01118,827,937,055.1117,990,488,890.09117,460,567,349.27
现金流量表
报告期2025-09-302025-06-302025-03-312024-12-31
经营活动产生的现金流量:
经营活动现金流入小计32,212,081,100.7421,388,993,511.9610,431,224,855.4743,172,147,821.77
经营活动现金流出小计28,830,312,535.0319,254,993,017.659,375,544,977.0238,695,166,559.55
经营活动产生的现金流量净额3,381,768,565.712,134,000,494.311,055,679,878.454,476,981,262.22
投资活动产生的现金流量:
投资活动现金流入小计2,888,011,838.782,012,663,450.931,275,324,161.382,405,322,190.85
投资活动现金流出小计4,399,844,279.572,872,400,465.891,460,415,546.786,018,645,562.07
投资活动产生的现金流量净额-1,511,832,440.79-859,737,014.96-185,091,385.4-3,613,323,371.22
筹资活动产生的现金流量:
筹资活动现金流入小计26,869,314,775.6616,848,567,870.256,711,769,738.5833,369,274,946.3
筹资活动现金流出小计30,113,741,396.8518,308,768,144.077,345,397,027.4234,371,861,283.66
筹资活动产生的现金流量净额-3,244,426,621.19-1,460,200,273.82-633,627,288.84-1,002,586,337.36
汇率变动对现金及现金等价物的影响-80,826,833.379,762,529.48,912,313.0327,989,327.43
现金及现金等价物净增加额-1,455,317,329.64-176,174,265.07245,873,517.24-110,939,118.93
期末现金及现金等价物余额7,936,132,457.479,215,275,522.049,637,323,304.359,391,449,787.11
补充资料:
现金及现金等价物的净增加额--176,174,265.07--110,939,118.93
  十大流通股东
  • 总资产(亿元)
  • 负债(亿元)
    截至第三季度最新总资产11812073.85万元，负债5730913.86万元。

利润表
报告期2025-09-302025-06-302025-03-312024-12-31
营业总收入29,393,385,360.9119,514,431,849.599,420,322,797.3441,067,195,862.59
营业总成本28,415,595,587.618,904,362,502.049,130,342,151.6839,397,511,520.64
其他经营收益
营业利润3,906,765,379.572,761,208,390.861,358,771,228.344,245,103,909.31
利润总额3,837,343,481.792,718,481,583.081,347,541,972.014,169,281,679.72
净利润3,056,091,951.682,100,210,564.8941,566,276.853,512,440,385
每股收益
其他综合收益-385,229,723.22-32,659,264.99-110,471,546.9543,142,250.33
综合收益总额2,670,862,228.462,067,551,299.81831,094,729.93,555,582,635.33
资产负债表
报告期2025-09-302025-06-302025-03-312024-12-31
流动资产:
流动资产合计32,145,481,005.8834,342,267,603.1934,438,609,708.9334,491,060,582.73
非流动资产:
非流动资产合计85,975,257,507.1384,485,669,451.9183,551,879,181.1682,969,506,766.54
资产总计118,120,738,513.01118,827,937,055.1117,990,488,890.09117,460,567,349.27
流动负债:
流动负债合计35,086,945,012.2236,023,336,557.9735,500,536,915.2537,452,669,252.79
非流动负债:
非流动负债合计22,222,193,608.3222,489,492,119.0321,640,050,046.7620,074,169,184.16
负债合计57,309,138,620.5458,512,828,67757,140,586,962.0157,526,838,436.95
所有者权益(或股东权益):
归属于母公司股东权益合计48,028,502,901.0547,397,623,662.6747,923,631,569.9547,261,106,860.73
股东权益合计60,811,599,892.4760,315,108,378.160,849,901,928.0859,933,728,912.32
负债和股东权益合计118,120,738,513.01118,827,937,055.1117,990,488,890.09117,460,567,349.27
现金流量表
报告期2025-09-302025-06-302025-03-312024-12-31
经营活动产生的现金流量:
经营活动现金流入小计32,212,081,100.7421,388,993,511.9610,431,224,855.4743,172,147,821.77
经营活动现金流出小计28,830,312,535.0319,254,993,017.659,375,544,977.0238,695,166,559.55
经营活动产生的现金流量净额3,381,768,565.712,134,000,494.311,055,679,878.454,476,981,262.22
投资活动产生的现金流量:
投资活动现金流入小计2,888,011,838.782,012,663,450.931,275,324,161.382,405,322,190.85
投资活动现金流出小计4,399,844,279.572,872,400,465.891,460,415,546.786,018,645,562.07
投资活动产生的现金流量净额-1,511,832,440.79-859,737,014.96-185,091,385.4-3,613,323,371.22
筹资活动产生的现金流量:
筹资活动现金流入小计26,869,314,775.6616,848,567,870.256,711,769,738.5833,369,274,946.3
筹资活动现金流出小计30,113,741,396.8518,308,768,144.077,345,397,027.4234,371,861,283.66
筹资活动产生的现金流量净额-3,244,426,621.19-1,460,200,273.82-633,627,288.84-1,002,586,337.36
汇率变动对现金及现金等价物的影响-80,826,833.379,762,529.48,912,313.0327,989,327.43
现金及现金等价物净增加额-1,455,317,329.64-176,174,265.07245,873,517.24-110,939,118.93
期末现金及现金等价物余额7,936,132,457.479,215,275,522.049,637,323,304.359,391,449,787.11
补充资料:
现金及现金等价物的净增加额--176,174,265.07--110,939,118.93
  主力控盘
  公司简介
复星医药 所属地域： 上海市 涉及概念： CRO概念，AI智能体，DeepSeek概念，智能医疗，减肥药，创新药，机器人概念，猴痘概念，家庭医生，辅助生殖，新冠检测，医美概念，生物疫苗，仿制药一致性评价，MSCI预期，医疗器械概念，细胞免疫治疗，证金持股，青蒿素，流感，沪股通，民营医院，融资融券，医疗改革
主营业务： 生物化学产品，试剂，生物四技服务，生产销售自身开发的产品，仪器仪表，电子产品，计算机，化工原料（除危险品），咨询服务；经营本企业自产产品及相关技术的出口业务，经营本企业生产、科研所需的原辅材料、机械设备、仪器仪表、零配件及相关技术的进口业务。【依法须经批准的项目，经相关部门批准后方可开展经营活动】
上市日期： 1998-08-07 每股净资产： 17.99元 每股收益： 0.95元 净利润： 25.23亿元 净利润增长率： 25.50%
营业收入： 293.93亿元 每股现金流： 1.27元 每股公积金： 6.12元 每股未分配利润： 10.57元 总股本： 26.70亿 流通股： 21.18亿



以上信息为合作方、加盟公司及会员收集，本站不拥有版权，版权归原作者所有，所载文章、数据仅供参考，据此操作，风险自负。

中 华 顶 尖 财 经 -- 中 华 顶 尖 网 络 信 息 服 务 中 心